HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $497, high $798, with mid-point at $647.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$647
Margin of safety
+34.1%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$426.37Price
Low $496.77
Mid $647.26
High $798.49
HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Local market density and scale
Local market density and scale advantages driving industry-leading margins.
Demographic tailwinds with an aging
Demographic tailwinds with an aging population ensuring consistent volume.
Bull thesis
Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.
HCA (HCA)'s margin set covers gross margin, operating margin, net margin, and free-cash-flow margin. The five-year trajectory is plotted so the reader can separate cyclical noise from secular trend.
Margin expansion or compression is read against the revenue base: if operating margin expands while revenue grows, that is operating leverage. If gross margin compresses, the cause (mix shift, input costs, pricing) is annotated in the numbers analysis.
Peer-relative margin context lives on the parent peers tab, which sets HCA's gross, operating, and net margins against four to five named peers from the same archetype and sector.
FCF margin is reported alongside operating margin so the reader can spot cases where capex intensity changes the cash-conversion read even when reported profitability is steady.
FAQ
HCA — frequently asked questions
Based on our latest analysis, HCA looks meaningfully undervalued. The current price is $426 versus a composite fair-value midpoint of $647 (range $497–$798), which implies roughly 51.8% upside to the midpoint.
Our composite fair-value range for HCA is $497–$798, with a midpoint of $647. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for HCA's archetype.
Our current rating for HCA is Strong Buy with a confidence score of 88/100. HCA is rated Strong Buy at $426.37 versus the reconciled fair value midpoint of $647.26, implying +51.81% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for HCA are: Severe Reimbursement Cuts; Structural Labor Shortage; Debt Cost Spiral. The single biggest risk is Severe Reimbursement Cuts: Government payers drastically compress Medicare/Medicaid rates to manage ballooning deficits, crushing margins.
Our current rating for HCA is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($497–$798) versus the current price of $426.
HCA is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for HCA.